ProFound Therapeutics Taps Veteran Scaler to Industrialize Its ‘Invisible’ Proteome Platform

CAMBRIDGE, Mass. – July 15, 2026 – In a move that signals a pivotal transition from discovery-stage science to industrial-scale drug development, ProFound Therapeutics has appointed Ainslie Little, Ph.D., as its new Chief Operating Officer. For a company built on the ambitious premise of charting a vast, “invisible” landscape of human proteins, the hire is less a routine personnel change and more a declaration of intent: the time has come to turn groundbreaking biology into a pipeline of first-in-class medicines.

ProFound, a 2020 graduate of Flagship Pioneering’s venture creation foundry, is built around its ProFoundry™ Platform, a technology designed to systematically uncover novel proteins hidden within what it calls the “expanded human proteome.” By bringing in Little, a seasoned executive with a formidable track record of scaling early-stage platform companies into major league players, ProFound is betting it has found the operational leader to translate its unique scientific map into tangible therapeutic assets.

The ‘Scaler’ Arrives

Ainslie Little is not a typical operations executive; she is a specialist in navigating the treacherous journey from preclinical startup to strategic powerhouse. Her resume reads like a playbook for building value in capital-intensive, high-science biotech ventures. Her seven-year tenure at BlueRock Therapeutics is a case in point. There, she was a key member of the executive team that scaled the company from a promising cell therapy startup into a firm so compelling that Bayer AG acquired it in a 2019 deal valued at up to $1 billion. Her experience guiding BlueRock through that critical growth phase, which included building its intellectual property portfolio and strategic partnerships, is precisely the expertise ProFound now requires.

More recently, as COO of Latus Bio, Little helped steer the AAV gene therapy company through a crucial period, culminating in a $97 million Series A financing round in May 2026 and the advancement of two candidates toward human trials. This background demonstrates a consistent ability to build the operational and strategic infrastructure necessary to support both platform innovation and clinical execution.

ProFound’s leadership is explicit about the strategic importance of this hire. "As the ProFoundry Platform continues to reveal new proteins and implicate them in disease, our priority is building the operational foundation to turn those discoveries into medicines," said John Lepore, M.D., CEO of ProFound Therapeutics and a CEO-Partner at Flagship Pioneering. He noted that Little has “repeatedly built and scaled the operations, strategy, and partnerships that carry an early platform company through critical growth phases.” Her appointment is a clear signal that ProFound is moving aggressively to industrialize its platform and build a sustainable drug development engine.

Charting the ‘Expanded Human Proteome’

ProFound’s core innovation lies in its pursuit of a biological dark matter. The “expanded human proteome” refers to the vast universe of proteins that are not coded by traditional genes. These proteins, arising from sources like non-canonical open reading frames (ncORFs) and alternative splicing events, have been historically “invisible” to science due to technological and computational limitations. They are often produced at low levels or are so different from known proteins that they have been dismissed as biological noise. ProFound’s thesis is that this hidden proteome contains a treasure trove of novel drug targets and therapeutic proteins.

The ProFoundry™ Platform is the engine designed to mine this territory. It combines three key pillars: ultra-sensitive protein detection technologies, such as advanced mass spectrometry, to find these elusive molecules; sophisticated computational biology and machine learning to analyze the data and predict function; and high-throughput experimental assays to validate the roles these new proteins play in health and disease.

This is the scientific frontier that attracted Little to the company. "ProFound is the only company positioned to explore the entire universe of proteins and drug targets from the expanded human proteome that have been invisible to date," she stated. "I was drawn to the chance to build the operational engine that propels that science more quickly into real medicines for the benefit of patients worldwide." Her role will be to ensure that as the ProFoundry platform generates new targets at an industrial pace, the rest of the organization—from strategy and IP to partnerships and pipeline management—is ready to capitalize on them.

The Flagship Blueprint for Breakthroughs

ProFound’s strategy cannot be fully understood without considering its origin. The company was conceived and launched within Flagship Labs, the innovation engine of Flagship Pioneering. This is the same venture creation firm behind blockbuster successes like Moderna and its revolutionary mRNA platform. Flagship’s model is not to simply invest in existing ideas, but to ask bold “what if” questions and build companies from scratch around the answers. ProFound, with its mission to explore an entirely new biological space, is a textbook example of the Flagship blueprint.

This affiliation provides more than just capital. It offers a deep well of strategic guidance, operational support, and access to a network that has proven adept at turning paradigm-shifting science into world-changing companies. The decision to bring in a COO with Little’s specific skill set is characteristic of Flagship’s methodical approach to company building. It marks the moment a portfolio company transitions from validating its core hypothesis to building a durable, value-generating enterprise.

While the competitive landscape for novel therapeutics is fierce—with companies developing everything from protein degraders (PROTACs) to RNA-targeting small molecules—ProFound’s approach is fundamentally different. Many competitors are finding new ways to drug known, but difficult, targets. ProFound is searching for entirely new targets that no one else has seen. By systematically mapping this uncharted territory, the company aims to create a proprietary and defensible pipeline of first-in-class medicines, a strategy that, if successful, promises not just incremental improvements but true breakthroughs.